DiaMedica Pharma - Bathi saben saham sajrone 12 wulan pungkasan DMAC

The current status of DiaMedica Therapeutics (DMAC) is based on the patents for the drug DM199, the success of which is determined by the results of medical trials. The EPS value trend on GURU.Markets, reaching -4.60, complements data on strategic alliances with hospitals to attract capital. Meanwhile, DiaMedica Therapeutics delegates protein production and testing to external contractors, maintaining a significant dependence on third-party capacities.
DiaMedica Therapeutics Inc. - rincian analitis lan metrik utama (DMAC)

For DiaMedica Therapeutics (DMAC), the year-over-year (TTM) EPS comparison serves as an indicator of the efficiency of development capitalization. This metric measures the percentage change in net income per share over a year, reflecting profitability dynamics. The calculation is based on the difference between the current and previous twelve-month periods. Amid geopolitical barriers and clinical trial disruptions, sharp peaks on the chart signal a risk of future margin compression.